08.22.19

Vida Ventures Closes $600 Million Vida II Fund to Support Life Science Innovation

08.22.19

Tishman Speyer and Bellco Capital Launch Breakthrough Properties, a First-of-Its-Kind Global Life Sciences Real Estate Platform

08.22.19

Kronos Bio Completes $105 Million Series A Financing

12.04.18

Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting

11.28.18

Kronos Bio Appoints Philip Gutry as Chief Business Officer to Expand Pipeline Opportunities

10.15.18

Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

10.10.18

Allogene Therapeutics Announces Pricing of Initial Public Offering

10.02.18

FierceBiotech names Kronos Bio as one of its “Fierce 15” Biotech Companies of 2018

09.27.18

Allogene Therapeutics Appoints Deborah M. Messemer, Former KPMG Managing Partner, to its Board of Directors

09.14.18

Allogene Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering

09.06.18

Allogene Therapeutics Completes a $120 Million Private Financing

08.28.18

Allogene Therapeutics Appoints David M. Tillett, Ph.D., as Senior Vice President, Head of Quality

08.14.18

Allogene Therapeutics Appoints Susie Jun, M.D., Ph.D., as Chief Development Officer

07.11.18

Allogene Therapeutics Announces Scientific Advisory Board

06.18.18

Allogene Therapeutics Announces Eric T. Schmidt, Ph.D. as Chief Financial Officer

06.05.18

UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance

06.04.18

Allogene Therapeutics Appoints Alison Moore, Ph.D. as Chief Technical Officer

05.30.18

Allogene Therapeutics Announces Board of Directors

05.23.18

Kronos Bio Appoints Dr. Norbert Bischofberger, Former Head of R&D for Gilead Sciences, as President and Chief Executive Officer and Completes $18 Million Seed Financing

05.21.18

UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)

05.16.18

Sienna Biopharmaceuticals to Present SNA-125 Pre-Clinical Psoriasis Data as Late-Breakter at the International Investigative Dermatology Congress

05.15.18

Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline

04.03.18

Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies

03.12.18

Sienna Biopharmaceuticals announces First Patient Dosed in Proof-Of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis

02.22.18

Kite, a Gilead Company, and Sangamo Therapeutics Announce Collaboration to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer

02.22.18

New Published Study Reports Cardiosphere-Derived Cells Improved Skeletal and Cardiac Muscle Function in Mouse Model of Duchenne Muscular Dystrophy

02.14.18

UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer

02.14.18

Sienna Biopharmaceuticals announces First Patient Dosed in First-In-Human Trial of Topical SNA-125

02.05.18

Capricor Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Duchenne Muscular Dystrophy Therapy

01.30.18

Hubble Contacts Launches Subscription Service in the UK

01.23.18

UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters’ Option

01.18.18

Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell Lymphoma

01.16.18

Capricor Announces Licensing of Additional Patent Applications from Cedars-Sinai Medical Center for Cellular and Exosome-based Technologies

01.08.18

UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer

12.12.17

UroGen Pharma Expands Clinical Development Leadership Team

12.11.17

Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

12.10.17

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma

12.07.17

Gilead Sciences and Kite to Acquire Cell Design Labs

11.29.17

Capricor Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for CAP-1002

11.15.17

Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Investigational Cell Therapy

11.06.17

UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder

11.02.17

UroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Directors

10.26.17

UroGen Pharma Expands Leadership Team, Appoints Industry Veterans Jeffrey Bova as Vice President of Commercial and James Ottinger as Vice President of Regulatory Affairs

10.24.17

Sienna Biopharmaceuticals announces First Patient Dosed In Phase 2B Trial of Topical SNA-120

10.18.17

Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy

10.06.17

Capricor Therapeutics Reports Intravenous Administration of CAP-1002 Shown to be Effective in Preclinical Models of Duchenne Muscular Dystrophy

10.04.17

Capricor Therapeutics Presents Positive Six-Month Results in Duchenne Muscular Dystrophy at World Muscle Society International Congress

10.03.17

Gilead Sciences Completes Acquisition of Kite Pharma, Inc.

09.06.17

UroGen Pharma Strengthens Management Team with the Appointment of Paul Chu as Vice President of Business Development

08.29.17

UroGen Pharma Receives FDA Fast Track Designation for MitoGel™ for the Treatment of Upper Tract Urothelial Carcinoma (UTUC)

08.28.17

Hubble Contacts Closes Series A-III Financing to Support Global Growth

08.28.17

Gilead Sciences to Acquire Kite Pharma for $11.9 Billion

08.08.17

Kite Submits Investigational New Drug (IND) Application for KITE-585, Anti-BCMA CAR-T Therapy Candidate for Multiple Myeloma

08.03.17

Kite Announces Landmark Study of Refractory Aggressive Non-Hodgkin Lymphoma (SCHOLAR-1) Outcomes Published in the Journal BLOOD

08.01.17

Sienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

08.01.17

Cell Design Labs Appoints Roger Sidhu, M.D. As Chief Medical Officer

07.31.17

Kite Files the Industry’s First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel

07.26.17

Sienna Biopharmaceuticals, Inc. Announces Pricing of Initial Public Offering of Common Stock

07.20.17

Kite Highlights Durable Complete Remissions Up to 56+ Months in Patients with Chemorefractory Aggressive Non-Hodgkin Lymphoma (NHL) after Anti-CD19 CAR T-Cell Therapy at the National Cancer Institute

07.19.17

Investigational New Drug Application for RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder Submitted to FDA by Allergan

07.18.17

Capricor Receives Rare Pediatric Disease Designation from FDA for CAP-1002 for Patients with Duchenne Muscular Dystrophy

06.27.17

Kite Named to the MIT Technology Review’s Annual 50 Smartest Companies List in Recognition for its Leadership in Establishing CAR-T Therapy

06.14.17

Sienna Biopharmaceuticals Appoints Erle Mast, Former CFO and Co-Founder of Clovis Oncology, to Board of Directors

06.07.17

Cell Design Labs Announces Issuance of Broad Patent for Chimeric Notch Receptor to Treat Cancer and other Diseases

06.05.17

Kite Reports 73 Percent of Patients Achieved MRD Negative Complete Remission in Updated Analysis From Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia

05.26.17

Kite Receives U.S. Food and Drug Administration Priority Review for Axicabtagene Ciloleucel

05.16.17

UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of Directors

05.10.17

UroGen Pharma Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option

05.08.17

Capricor Therapeutics Announces Private Placement of Common Stock

04.25.17

Capricor Therapeutics Announces Positive Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy

04.24.17

UroGen Pharma Welcomes New Board Member Kate Falberg

04.24.17

Sienna Biopharmaceuticals Announces $40 Million Series B Financing

04.06.17

Kite Wins ‘Clinical Trial Result of the Year’ for its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 Clinical and Research Excellence Awards

04.03.17

UroGen Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial of MitoGel™ for Treatment of Low-Grade Upper Tract Urothelial Carcinoma

04.02.17

Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Cancer Research Annual Meeting

03.31.17

New Gene Therapy for Cancer Offers Hope to Those With No Options Left

03.31.17

Kite Completes Submission of U.S. Biologics License Application (BLA) for Axicabtagene Ciloleucel as the First CAR-T Therapy for the Treatment of Patients With Aggressive Non-Hodgkin Lymphoma (NHL)

03.24.17

Richard Peterson Joins Sienna Biopharmaceuticals As Chief Financial Officer

03.20.17

Hubble Contacts Wants To Do For Contact Lenses What Harry’s Did For Razors

03.15.17

Cell Design Labs Announces Issuance of a Broad Patent for Programmable CAR-T Cells to Treat Cancer and Other Diseases

03.14.17

Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell Therapy

03.08.17

Kite Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

03.07.17

Hubble raises $16.5 million to deliver affordable daily contact lenses

02.28.17

Kite Announces Positive Topline Primary Results of Axicabtagene Ciloleucel from First Pivotal CAR-T Trial in Patients with Aggressive Non-Hodgkin Lymphoma

02.28.17

Former Allergan Chief David Pyott Signs on as Special Advisor to Sienna Biopharmaceuticals

02.09.17

Cell Design Labs’ Scientific Founder Co-Authors Review Article Illustrating Power and Potential of Engineered Human Cells to Treat Cancer

01.10.17

Kite Pharma and Fosun Pharma Establish Joint Venture in China to Develop and Commercialize Autologous T-Cell Therapies to Treat Cancer

01.09.17

Kite Pharma Establishes a Strategic Partnership With Daiichi Sankyo to Develop and Commercialize Axicabtagene Ciloleucel (KTE-C19) in Japan

01.03.17

Kite Pharma Submits Investigational New Drug (IND) Application for KITE-718, an Investigational Next Generation T-Cell Receptor (TCR) Therapy Targeting Cancer Antigens MAGE A3 and MAGE A6

12.12.16

Kite Pharma Announces Publication of T-Cell Therapy Targeting Mutant KRAS in Cancer by the National Cancer Institute (NCI) in New England Journal of Medicine

12.12.16

UroGen Pharma Announces FDA Acceptance of Investigational New Drug Application for MitoGel, a Novel Sustained Release Formulation of Mitomycin C, for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma

12.06.16

Sienna Biopharmaceuticals Acquires Creabilis plc

12.04.16

Kite Pharma Reports 82 Percent of Patients Achieved Complete Remission in Preliminary Analysis from Phase 1 ZUMA-3 and ZUMA-4 Trials of KTE-C19 in Adult and Pediatric Patients with High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia

12.04.16

Kite Pharma Initiates Rolling Submission of U.S. Biologics License Application (BLA) for KTE-C19, its Investigational anti-CD19 CAR-T Therapy, for the Treatment of Patients with Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL)

11.10.16

Capricor Therapeutics Announces Plans to Expand Clinical Development Program in Duchenne Muscular Dystrophy to Evaluate Peripheral and Respiratory Muscle Function

11.01.16

Hubble Contacts raises $7.2 million to deliver disposable lenses direct to consumers

11.01.16

This startup wants to deliver affordable contact lenses straight to your door

10.31.16

Hubble Wants to Do for Contact Lenses What Warby Parker Did for Eyeglasses

10.31.16

Capricor Therapeutics Presents Positive 12-Month Results from DYNAMIC at TCT 2016

10.20.16

Capricor Therapeutics Awarded Up to $4.2 Million from National Institutes of Health to Evaluate Exosomes for Hypoplastic Left Heart Syndrome

10.19.16

Kite Pharma Details KTE-C19 Launch Preparedness and Near-Term, Next Generation CAR/TCR Product Candidates at Investor Day

10.14.16

UroGen Pharma Announces Agreement to License RTGel™ for Use with Neurotoxins to Allergan

10.06.16

Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL)

09.29.16

CELL DESIGN LABS ANNOUNCES PEER-REVIEWED PUBLICATION VALIDATING ABILITY TO PROGRAM IMMUNE CELLS TO TREAT CANCER AND AUTOIMMUNE DISEASE

09.26.16

Kite Pharma Announces Positive Topline KTE-C19 Data from ZUMA-1 Pivotal Trial in Patients with Aggressive Non-Hodgkin Lymphoma (NHL)

09.26.16

Capricor Therapeutics Awarded $2.4 Million from U.S. Department of Defense to Support Manufacturing Process Development for Therapeutic Exosomes

09.21.16

Capricor Therapeutics Announces Closing of Public Offerings Raising Approximately $10.0 Million in Net Proceeds

09.20.16

Kite Pharma Announces Exclusive License with the National Institutes of Health for Multiple Neoantigen Directed T-Cell Receptor (TCR) Product Candidates to Treat Solid Tumors Expressing Mutated KRAS

08.16.16

Arno Completes $2.8 Million Private Placement

07.27.16

Kite Pharma Announces Exclusive License with the National Institutes of Health for Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) Product Candidate to Treat B-Cell Malignancies

07.25.16

Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies

07.12.16

Sienna Biopharmaceuticals Announces Second Closing of Series A Financing

06.20.16

Kite Pharma Expands Development of T-Cell Receptor (TCR) Therapies Targeting HPV-Associated Cancers in Partnership with the National Cancer Institute (NCI)

06.20.16

Kite Pharma Opens State-of-the-Art T-Cell Therapy Manufacturing Facility

06.16.16

Capricor Therapeutics Reports Positive 12-Month Data from the DYNAMIC Clinical Trial

06.06.16

Kite Pharma Presents Ongoing Complete Responses at 9 Months in Phase 1 of ZUMA-1 in Patients with Chemorefractory Non-Hodgkin Lymphoma

06.06.16

Kite Pharma Announces the First Meta-Analysis of Outcomes in Chemorefractory Diffuse Large B-Cell Lymphoma (SCHOLAR-1)

06.06.16

Kite/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions in Advanced Non-Hodgkin Lymphoma

06.02.16

Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular ‘On/Off Switches’ for CAR T-Cell Immunotherapies

06.02.16

Cell Design Labs Executes Series of Private Financings

05.05.16

UroGen Pharma Announces Three Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association’s 2016 Annual Meeting

05.02.16

Kite Pharma Announces FDA Orphan Drug Designations for KTE-C19 in Five Additional Indications

04.28.16

Sienna Biopharmaceuticals Announces $34 Million Series A Financing

04.19.16

Arno Therapeutics to Focus Clinical Developmental Activities on Advanced Prostate Cancer in First-of-its-Kind Phase II Study of Onapristone in Combination with ZYTIGA

04.19.16

Kite Pharma Presents Updated Phase 1 Results from ZUMA-1 at the American Association of Cancer Research (AACR) Annual Meeting

04.04.16

Capricor Therapeutics Announces DSMB Recommends Continuation of HOPE-Duchenne Clinical Trial

03.21.16

Arno Therapeutics Advances Phase I/II Trial Evaluating Onapristone in Prostate Cancer to Phase II

03.17.16

Kite Pharma Announces Clinical Collaboration to Evaluate Two Novel Immunotherapies for Patients with Non-Hodgkin Lymphoma

03.17.16

Capricor Awarded $3.4 Million Grant from California Institute for Regenerative Medicine

03.16.16

Kite Pharma Announces Clinical and Manufacturing Updates on KTE-C19 and MAGE-A3 Product Candidates at the Annual Meeting of the American Association for Cancer Research (AACR)

02.22.16

Capricor Therapeutics Announces the First Patient with Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated with CAP-1002 in the HOPE-Duchenne Phase I/II Clinical Trial

02.08.16

UroGen Pharma Strengthens Board of Directors and Senior Management Team

01.15.16

Capricor Therapeutics Announces $4 Million Registered Direct Offering

01.13.16

UroGen Pharma Strengthens Leadership Team and Expands Uro-Oncology Clinical Pipeline with Addition of TLR-7 Agonist Phase 2 Asset

01.13.16

Arno Therapeutics Completes $7.4 Million Common Stock Financing

01.13.16

Kite Pharma and Leiden University Medical Center Sign Research and License Agreement for T Cell Receptors Targeting HPV-Associated Cancers

01.07.16

Kite Pharma Expands Its Clinical and Research Partnership With the National Cancer Institute (NCI) for Next-Generation CAR Programs to Treat B-Cell Malignancies

01.05.16

Capricor Therapeutics to Present at Biotech Showcase 2016

12.21.15

Kite Pharma Appoints Industry Leader Shawn Cline Tomasello as Chief Commercial Officer

12.10.15

Capricor Therapeutics to Present at the 2015 JMP Securities DMD Forum

12.08.15

Kite Pharma Announces Proposed Public Offering of Common Stock

12.07.15

Kite Pharma Receives FDA Breakthrough Therapy Designation for KTE-C19 for the Treatment of Refractory, Aggressive Non Hodgkin Lymphoma (NHL)

12.07.15

Kite Pharma Initiates the ZUMA-4 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Children and Young Adults

12.07.15

Kite Pharma Presents Phase 1 Results From ZUMA-1 at the 57th American Society of Hematology (ASH) Annual Meeting

12.07.15

Kite Pharma Announces Clinical Biomarker Results of Anti-CD19 CAR T Cell Therapy at the 57th American Society of Hematology Annual Meeting (ASH)

12.03.15

Kite Pharma and GE Global Research Announce Strategic Collaboration to Automate Manufacturing of Engineered T Cell Therapies

12.02.15

Kite Pharma Initiates the ZUMA-3 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Adult Subjects

11.24.15

Capricor Therapeutics to Present at the 2015 Piper Jaffray Healthcare Conference

11.16.15

Arno Therapeutics Reports Third Quarter 2015 Financial Results and Business Update

11.12.15

Kite Pharma Reports Third Quarter 2015 Financial Results and Provides Business Update

11.12.15

Capricor Therapeutics Reports Third Quarter 2015 Business & Financial Highlights

11.09.15

Kite Pharma Initiates Phase 2 Clinical Study of KTE-C19 (ZUMA-2) in Patients With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) to Support Registration for a Second Indication

11.09.15

Capricor Therapeutics Presents Positive Data from the DYNAMIC Clinical Trial at 2015 American Heart Association Scientific Sessions

11.05.15

Capricor Therapeutics To Present Data from the DYNAMIC Clinical Trial at American Heart Association Scientific Sessions 2015

11.05.15

Kite Pharma to Present Four Abstracts, including Safety and Efficacy Data from the KTE-C19 Phase 1 Study in Patients with Refractory, Aggressive NHL (ZUMA-1), at the 57th American Society of Hematology Annual Meeting (ASH)

11.04.15

Capricor Therapeutics to Hold Third Quarter 2015 Business Update and Financial Results Conference Call on November 12, 2015 at 4:30 p.m. EST

11.04.15

Kite Pharma to Present at Upcoming Investor Conferences in November 2015

10.29.15

Capricor Therapeutics and CureDuchenne to Host Webinar on November 3, 2015 at 3:00 p.m. ET

10.27.15

Kite Pharma and Alpine Immune Sciences Announce Research Collaboration and License Agreement to Enhance Immune Response in the Tumor Microenvironment

10.27.15

Kite Pharma Initiates ZUMA-1 Phase 2 in Patients With Aggressive, Refractory Non-Hodgkin’s Lymphoma (NHL) to Support Registration of KTE-C19

10.21.15

Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains

10.15.15

Kite Pharma Receives Positive Opinions for Orphan Drug Designation in the European Union (EU) for KTE-C19 in Three Additional Hematological Indications

10.15.15

Kite Pharma Announces Exclusive License with the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat Tumors Expressing MAGE

10.07.15

Kite Pharma Commends Steven A. Rosenberg, M.D., Ph.D., on the Prestigious Medal of Honor Award From the American Cancer Society

10.01.15

Kite Pharma Announces Peer-Reviewed Publication of T Cell Receptor Based Product Candidate to Treat HPV-Associated Cancers

09.30.15

Capricor Therapeutics to Present at 2015 Stem Cell Meeting on the Mesa

09.25.15

Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference

09.24.15

Arno Therapeutics’ AR-13 Data Show Promise as Potential New Therapeutic Option for Cystic Fibrosis Patients with Serious Bacterial Infections

09.19.15

Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs

09.19.15

Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Exposition

09.15.15

Franz B. Humer, Former Chairman and CEO of Roche Group, Appointed to Kite Pharma’s Board of Directors

09.14.15

Kite Pharma Expands Collaboration With Netherlands Cancer Institute (NKI)

09.14.15

AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015

09.11.15

Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite’s Lead Cancer T-Cell Immunotherapy

09.03.15

Kite Pharma to Participate in Upcoming Investor Conferences in September 2015

09.03.15

Kite Pharma Commends Honors Conferred to Scientific Advisory Board Members for Their Significant Contributions to Medicine

09.01.15

Arno Therapeutics to Present at 17th Annual Rodman & Renshaw Conference

08.18.15

Arno Therapeutics Receives Authorization to Proceed with Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer

08.17.15

Kite Pharma Provides Update on KTE-C19 Clinical Trial

08.14.15

Kite Pharma to Hold Conference Call to Provide a Corporate Update on Monday, August 17, 2015

08.14.15

Arno Therapeutics Reports Second Quarter 2015 Financial Results and Business Update

08.13.15

Capricor Therapeutics Reports Second Quarter 2015 Business & Financial Highlights

08.10.15

Kite Pharma Reports Second Quarter 2015 Financial Results

08.06.15

Kite Pharma to Host Second Quarter 2015 Financial Results Conference Call and Webcast

08.06.15

Capricor Therapeutics to Hold Second Quarter 2015 Business Update and Financial Results Conference Call on August 13, 2015 at 4:30 p.m. EDT

08.05.15

Kite Pharma to Present at the Canaccord Genuity 35th Annual Growth Conference

08.04.15

Capricor Therapeutics Appoints Deborah Ascheim, M.D. as Chief Medical Officer

07.01.15

Kite Pharma and The Leukemia & Lymphoma Society(R) Enter Into Collaboration to Enhance the Development of KTE-C19 in Refractory Aggressive Non-Hodgkin Lymphoma and Launch CAR T-Cell Therapy Educational Programs

06.22.15

Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers

06.22.15

Capricor Therapeutics, Inc. (Nasdaq: CAPR) to Ring The Nasdaq Stock Market Closing Bell

06.17.15

Capricor Therapeutics Appoints Houman Hemmati M.D., Ph.D. to Vice President of Medical and Clinical Development for New Therapies

06.16.15

Kite Pharma to Host Investor Day on June 23, 2015

06.15.15

Capricor Therapeutics and CureDuchenne to Host Webinar on June 19, 2015 at 3:00 p.m. ET

06.08.15

Capricor Announces Receipt of FDA Clearance for the Phase I/II Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Related Cardiomyopathy

06.04.15

Arno Therapeutics Announces Issuance of First Onapristone Patent

06.03.15

Arno Therapeutics Announces Cooperative Research and Development

06.02.15

Kite Pharma Presents Clinical Biomarker Results in Patients Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy at the 2015 ASCO Annual Meeting

05.29.15

Kite Pharma to Present Clinical Biomarkers From Patients Treated With Anti-CD19 Chimeric Antigen Receptor T Cell Therapy at the 2015 ASCO Annual Meeting

05.28.15

Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research

05.26.15

Capricor Therapeutics to Participate in Two Upcoming Investor Conferences in June

05.26.15

Kite Pharma to Present at the Jefferies 2015 Global Healthcare Conference

05.12.15

Kite Pharma to Report First Quarter Financial Results on Friday, May 15, 2015

05.12.15

Capricor Therapeutics Reports First Quarter 2015 Financial & Business Highlights

05.07.15

Arno Therapeutics Receives USPTO Notice of Allowance for Two Important Patents Covering Lead Compound Onapristone

05.05.15

Capricor Therapeutics to Hold First Quarter 2015 Business Update and Financial Results Conference Call on May 12, 2015 at 4:30 p.m. EDT

04.30.15

Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases

04.29.15

Arno Therapeutics to Present Three Posters Supporting Onapristone Development at ASCO Annual Meeting 2015

04.22.15

Capricor Granted FDA Orphan Drug Designation for Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy

04.21.15

Arno Therapeutics to Present Promising Data from Phase I Trial of Onapristone at AACR Annual Meeting 2015

04.21.15

Kite Pharma Commends Honors Conferred to Drs. Owen Witte and Steven A. Rosenberg at the 2015 American Association for Cancer Research (AACR) Annual Meeting

04.13.15

Arno Therapeutics Announces Three Poster Presentations at Upcoming AACR Annual Meeting 2015

04.10.15

Kite Pharma to Present at the 2015 Jefferies Immuno-Oncology Summit in Boston

04.08.15

Capricor Completes Enrollment of Initial Phase of DYNAMIC Clinical Trial of Cardiosphere-Derived Cell Therapy for Treatment of Advanced Heart Failure

04.06.15

Kite Pharma Announces Publication in Science of Cancer Immunotherapy Articles Authored by Lead Collaborators at the National Cancer Institute and the Netherlands Cancer Institute

03.31.15

Capricor Therapeutics Completes Enrollment of Phase II Clinical Trial for Cenderitide to Treat Heart Failure

03.31.15

Arno Therapeutics Reports Fourth Quarter 2014 Financial and Business Update

03.26.15

Kite Pharma Reports Full-Year and Fourth Quarter 2014 Financial Results

03.25.15

Kite Pharma to Report Fourth Quarter and Full Year 2014 Financial Results on March 26th, 2015

03.24.15

New Data Supporting Arno Therapeutics’ HDAC inhibitor AR-42 Published in The Journal of Urology

03.23.15

Capricor Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25, 2015 in New York

03.18.15

Capricor Therapeutics Reports Fourth Quarter and Full Year 2014 Financial & Business Highlights

03.17.15

Kite Pharma Strengthens Its T Cell Receptor (TCR) Cancer Gene Therapy Platform Through Acquisition of T-Cell Factory B.V. (TCF(TM))

03.12.15

Capricor Therapeutics to Hold Fourth Quarter 2014 Business Update Conference Call on March 18, 2015 at 4:30 p.m. EDT

03.10.15

Capricor Therapeutics to Present at the 27th Annual ROTH Conference

03.06.15

Kite Pharma to Present at the 2015 Barclays Global Healthcare Conference

03.05.15

Capricor Announces Enrollment of its Phase II Clinical Trial for Cenderitide to Treat Heart Failure

03.02.15

Kite Pharma Expands Its Research and Development Collaboration With the National Cancer Institute to Develop a Next Generation of Cancer Immunotherapy Products for Solid Tumors

02.23.15

Kite Pharma to Present at the Cowen and Company 35th Annual Health Care Conference

02.19.15

Kite Pharma Establishes Manufacturing Capabilities to Support Development and Commercialization of CAR and TCR Cancer Immunotherapy Products

02.03.15

Kite Pharma Expands and Strengthens Leadership Team

02.02.15

Kite Pharma to Present at the 17th Annual BIO CEO & Investor Conference

01.22.15

Kite Pharma Announces Expanded Agreement with Tel Aviv Sourasky Medical Center and Pioneering Researcher Professor Zelig Eshhar to Develop Novel Chimeric Antigen Receptor (CAR) Approaches for Cancer Immunotherapy

01.19.15

Kite Pharma Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process

01.12.15

Capricor Therapeutics Initiates the DYNAMIC Clinical Trial for the Treatment of Advanced Heart Failure

01.12.15

Capricor Therapeutics Announces $10 Million Private Placement of Common Stock

01.09.15

Kite Pharma Expands Senior Management Team With Appointment of Claudine Prowse, Ph.D., as SVP, Corporate Communications and Investor Relations

01.08.15

Arno Therapeutics to Present at 11th Annual Noble Equity Conference

01.08.15

Kite Pharma Announces Addition of Scott N. Bernstein as Vice President of Intellectual Property Law

01.07.15

Kite Pharma to Present at the 33rd Annual J.P. Morgan Healthcare Conference

01.07.15

Kite Pharma Announces Exclusive License With the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat HPV-Associated Cancers

01.06.15

Kite Pharma Granted Orphan Drug Designation in the European Union for KTE-C19, Kite’s Lead Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy

01.05.15

Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies

12.22.14

Kite Pharma Submits Investigational New Drug Application for Phase 1/2 Trial of KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, for the Treatment of Refractory Aggressive Non-Hodgkin Lymphoma

12.16.14

Kite Pharma Added to the NASDAQ Biotechnology Index

12.10.14

Arno Therapeutics Doses First Patient in Expansion Stage of Modified Phase I/II Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors

12.10.14

Kite Pharma Announces Pricing of Follow-On Offering

12.09.14

Arno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014

12.04.14

Arno Therapeutics Appoints Alexander Zukiwski, M.D. to Board of Directors –

12.02.14

Capricor Therapeutics Announces Linda Marban, Ph.D. Will Present a Company Overview and Serve as an Expert Panelist at Piper Jaffray’s 26th Annual Healthcare Conference

11.26.14

Kite Pharma Files Registration Statement for Proposed Follow-On Offering

11.24.14

Arno Therapeutics to Present at LD Micro Conference 2014

11.18.14

Capricor Therapeutics Announces Positive Pre-Clinical Data for Cardiosphere-Derived Cells (CDCs) on Duchenne Muscular Dystrophy Cardiomyopathy

11.18.14

Capricor Therapeutics Announces Favorable ALLSTAR Phase I Safety Results

11.18.14

Kite Pharma Announces Presentations at the Upcoming 56th American Society of Hematology Annual Meeting

11.17.14

Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite’s Lead Investigational Cancer Immunotherapy

11.14.14

Arno Therapeutics Reports Third Quarter 2014 Financial and Business Update

11.14.14

Kite Pharma Reports Third Quarter 2014 Results

11.12.14

Capricor Therapeutics Reports Third Quarter 2014 Financial & Business Highlights

11.07.14

Capricor Therapeutics to Hold Duchenne Muscular Dystrophy Data Presentation Call on November 18, 2014 at 9:30 a.m. ET

11.05.14

Kite Pharma to Participate in Three Upcoming Investor Conferences in November 2014

10.31.14

Capricor Therapeutics to Hold Third Quarter 2014 Business Update Conference Call on November 12, 2014 at 4:30 p.m. ET

10.29.14

Arno Therapeutics’ Executive Selected to Present at 5th Annual Clinical Affairs and Regulatory Approvals for Diagnostics Conference

10.27.14

Arno Therapeutics Advances Phase I Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors to Expansion Stage

10.23.14

Arno Therapeutics to Present Encouraging Data from Ongoing Phase I/II Trial Evaluating Onapristone in CRPC at 21st Annual PCF Scientific Retreat

10.14.14

Capricor Therapeutics Announces Acquisition of Intellectual Property Rights to Family of Natriuretic Peptides From Medtronic, Inc.

10.13.14

Kite Pharma Announces Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells

10.09.14

Capricor Therapeutics Announces Plans to Pursue a Cenderitide Clinical Program and Enters Into Research Support Agreement With Insulet Corporation

10.06.14

Capricor Announces Plans to Pursue Clinical Program for the Treatment of Duchenne Muscular Dystrophy With Cardiosphere-Derived Cells (CDCs)

10.03.14

Kite Pharma to Participate in Gene Therapy Panel at the BIO Investor Forum

09.30.14

Arno Therapeutics to Present at the 13th Annual BIO Investor Forum

09.18.14

Capricor Presents Safety and Preliminary Efficacy Results From ALLSTAR Phase I Clinical Trial at TCT 2014

09.18.14

Arno Therapeutics’ Executive Selected to Chair World CDx Boston 2014

09.16.14

Kite Pharma to Present at the 21st Annual NewsMakers in the Biotech Industry Investment Conference on Friday, September 26

09.08.14

Arno Therapeutics to Present at Upcoming Investor Conferences

08.26.14

Kite Pharma to Present at the Citi 9th Annual Biotech Conference on Wednesday, September 3

08.25.14

Kite Pharma Announces Patients With Aggressive Non-Hodgkin’s Lymphoma Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells at the National Cancer Institute (NCI)

08.14.14

Arno Therapeutics Reports Second Quarter 2014 Financial and Business Update

08.14.14

Kite Pharma Reports Second Quarter 2014 Results

08.13.14

Capricor Therapeutics Reports Second Quarter 2014 Financial & Business Highlights

08.04.14

Capricor Therapeutics to Hold Second Quarter 2014 Business Update Conference Call on August 13, 2014 at 4:30 p.m. Eastern Time

07.18.14

Arno Therapeutics, Inc. Appoints Alexander Zukiwski, M.D. as Interim Chief Executive Officer and Mr. Lawrence Kenyon as Chief Operating Officer

07.16.14

Capricor Announces Encouraging Results From Phase I ALLSTAR Trial; Phase II Trial Underway

06.23.14

Kite Pharma Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

06.23.14

Capricor Therapeutics to Present at the First Regenerative Medicine Forum at BIO International Convention

06.20.14

Kite Pharma Announces Pricing of Initial Public Offering

06.19.14

Capricor Therapeutics Speaks at Panel on Regulation of Stem Cell-Derived Therapeutic Products at DIA 2014 50th Annual Meeting

05.29.14

Arno Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference

05.28.14

Capricor Therapeutics to Present on Exosomes as a Basis for Innovative Platform Technology at 11th International Symposium on Stem Cell Therapy and Cardiovascular Innovations

05.15.14

Capricor Therapeutics Reports First Quarter 2014 Business Highlights

05.15.14

Arno Therapeutics Reports First Quarter 2014 Financial and Business Update

05.14.14

Capricor Therapeutics to Hold First Quarter 2014 Business Update Conference Call on May 15, 2014 at 4:30 p.m. Eastern Time

05.14.14

Arno Therapeutics to Outline Two Phase I Studies Evaluating Onapristone in Men’s and Women’s Cancers at 2014 ASCO Annual Meeting

05.06.14

Capricor Therapeutics Enters Into Exclusive License With Cedars-Sinai Medical Center for Exosome-Related IP Portfolio

05.05.14

Arno Therapeutics Announces Clinical Abstracts Accepted at 2014 ASCO Annual Meeting

04.14.14

Kite Pharma Expands Leadership Team and Announces Senior Management Promotions

04.11.14

Kite Pharma Expands Company’s Board of Directors with the Appointment of Jonathan M. Peacock

04.07.14

Arno Therapeutics Enrolls First Patient in a Phase I/II Trial Evaluating Onapristone in Men with Advanced Castration-Resistant Prostate Cancer

04.02.14

Kite Pharma Announces the Appointment of Arie Belldegrun, M.D., as President and Chief Executive Officer

04.01.14

Arno Therapeutics Reports 2013 Financial Results and Provides Update on Strategic and Operational Milestones

03.31.14

Kite Pharma Announces FDA Orphan Drug Designation for Anti-CD19 T Cell Cancer Immunotherapy Product

03.28.14

Capricor Therapeutics to Present ALLSTAR Phase I Trial Data at ACC Annual Meeting 2014

03.26.14

Arno Therapeutics to Present Three New Studies Supporting the Clinical Development of Onapristone at AACR Annual Meeting 2014

03.24.14

Arno Therapeutics Board of Directors Appoints Randy Thurman as Vice Chairman

03.10.14

Capricor Therapeutics to Present at Two Upcoming Investor Conferences

03.05.14

Arno Therapeutics to Present at 26th Annual ROTH Conference

03.04.14

Arno Therapeutics Granted Exclusive License for Oncology Diagnostic Technique by University of Minnesota

02.27.14

Arno Therapeutics Appoints Lawrence A. Kenyon Chief Financial Officer

01.21.14

Arno Therapeutics Enrolls First Patient in a Phase I Trial to Evaluate Lead Compound Onapristone in Progesterone Receptor Positive Solid Tumors

01.17.14

Kite Pharma Appoints Rizwana F. Sproule, Ph.D., as Vice President, Regulatory Affairs

01.13.14

Arno Therapeutics Expands Management Team with Additions of Two Scientific Leaders

01.09.14

NeoStem’s Subsidiary, Progenitor Cell Therapy (PCT), to Provide Process Development and Manufacturing Services to Kite Pharma

01.09.14

Arno Therapeutics to Present at Biotech Showcase 2014

01.08.14

Kite Pharma Appoints Cynthia M. Butitta as Chief Financial Officer

01.07.14

Arno Therapeutics Selects Leica Biosystems to Develop Companion Diagnostic for Targeted Oncology Therapy Onapristone

01.06.14

Capricor Therapeutics and Janssen Biotech, Inc. Enter Into Collaboration Agreement and Exclusive License Option

12.20.13

Capricor Therapeutics Announces Ticker Symbol Change to CAPR

12.17.13

Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack

12.14.13

Arno Therapeutics to Present Data on Two Potential Predictive Biomarkers at the San Antonio Breast Cancer Symposium 2013

12.07.13

Kite Pharma’s Lead Program with the National Cancer Institute (NCI) Demonstrates Positive Results in Patients with Aggressive Non-Hodgkin’s Lymphoma

12.07.13

Kite Pharma to Present at the 32nd Annual J.P. Morgan Healthcare Conference

12.07.13

New studies demonstrate that modified T cells are effective in treating blood-borne cancers

11.21.13

Capricor and Nile Therapeutics Complete Merger to Form Capricor Therapeutics, Inc.

11.18.13

Arno Therapeutics Adds Steven Rubin, EVP of OPKO Health, Inc., as Board Observer

09.28.13

Arno Therapeutics to Present Data Validating Target Biomarker at European Cancer Congress 2013

09.09.13

Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors

08.08.13

Kite Pharma Appoints Leading Cancer Immunotherapy Experts to its Scientific Advisory Board

07.08.13

Capricor and Nile Therapeutics Announce Merger Agreement

06.21.13

Nile Therapeutics Announces Filing of Annual and Quarterly Reports to Become Current on SEC Filings

06.03.13

Arno Therapeutics to Collaborate With Veridex on Development of Diagnostic Test

05.30.13

Kite Pharma Appoints Keith Nolop, M.D. Chief Medical Officer

05.15.13

Kite Pharma Completes $35 Million Series A Preferred Stock Financing

05.15.13

Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting

05.10.13

Arno Therapeutics to Collaborate with Clarient for Development of Diagnostic Test

04.08.13

Arno Therapeutics Reports Activated Progesterone Receptors Predictive of Response to Onapristone

03.19.13

Arno Therapeutics Engages The Ruth Group for Investor Relations and Public Relations Counsel

03.07.13

Capricor, Inc. Appoints Anthony Davies, Ph.D., Chief Technology Officer

01.31.13

Arno Therapeutics, Inc. Appoints Randy Thurman to the Board of Directors

12.19.12

Arno Therapeutics Completes $14.9 Million Financing To Advance Lead Clinical Compounds

12.05.12

Arno Therapeutics Reports Findings of New Diagnostic Technique the Potential to Identify Patients with Cancer Who May Respond to Treatment with Onapristone

11.27.12

Arno Therapeutics Completes $12.7 Million Financing

11.09.12

Arno Therapeutics Reports Progress in Development of Clinical Biomarkers to Support Treatment of Breast Cancer with Onapristone

10.16.12

Kite Pharma Partners with the National Cancer Institute to Develop Novel Cellular Immunotherapy Clinical Products

10.01.12

US launch of Forfivo XL (bupropion HCl extended-release tablets)

06.07.12

Arno Therapeutics Announces Additional Orphan-Drug Designations for AR-42 in Europe

05.11.12

Arno Therapeutics Announces Orphan-Drug Designation for AR-42 in Europe

02.21.12

Arno Therapeutics Receives Two Orphan-Drug Designations for AR-42 in Treatment of Central-Nervous-System Tumors

02.14.12

Arno Therapeutics Announces Exclusive Licensing Agreement with Invivis Pharmaceuticals to Develop Cancer Drug

01.01.12

US launch of Fluoxetine Tablets, 60 mg

07.19.11

Veterans of J&J, Pfizer, and Medimmune Seek to Transform Arno into Oncology Powerhouse

07.11.11

Kite Pharma Appoints Adrian Bot, M.D., Ph.D., as Chief Scientific Officer

06.27.11

Arno Therapeutics Names Alexander Zukiwski, M.D., Vice President and Chief Medical Officer

06.23.11

Arno Therapeutics Reports Positive Interim Results from Glioblastoma Study; Phase II Enrollment to Continue

05.26.11

Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients

05.03.11

Nile Therapeutics Announces Dosing of First Patient in Phase I Study of Cenderitide

04.28.11

Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer

03.31.11

Nile Therapeutics Receives Fast Track Designation for Cenderitide for Post-Acute Indication

03.09.11

Kite Pharma Raises $15 Million in Initial Round of Financing and Appoints David Bonderman to Board of Directors

02.28.11

Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure

02.28.11

Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease

09.20.10

Kite Pharma Appoints Dr. Gloria Lee Chief Medical Officer

09.16.10

Aya Jakobovits, Ph.D., Named President and CEO of Kite Pharma, Inc.

09.13.10

Arno Therapeutics, Inc. Raises $15 Million in Private Placement To Advance Clinical Development of Oncology Compounds

06.17.10

Arno Therapeutics Announces Dosing of First Patient in a Phase I/IIa Study of AR-42, a broad spectrum histone and non-histone deacetylation inhibitor (pan-DAC)

12.17.09

Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 in Patients with Glioblastoma Multiforme (GBM)

12.15.09

Arno Therapeutics Announces Poster Presentation at ASH Annual Meeting Demonstrating Anti-Leukemic Stem Cell Activity of AR-42

09.01.09

Acquired US license and supply agreement for EDG003

08.27.09

Arno Therapeutics Announces Dosing of First Patient in Phase I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway

07.23.09

Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 (formerly DB-67) in Patients with Myelodysplastic Syndrome

05.27.09

Arno Therapeutics Announces Three Poster Presentations at ASCO Annual Meeting

05.11.09

FDA Accepts Arno Therapeutics’ IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway

05.04.09

Arno Therapeutics to Deregister its Common Stock under the Exchange Act

03.31.09

Arno Therapeutics Reports 2008 Year-End Financial Results

03.17.09

FDA Accepts IND for Arno Therapeutics’ Pan-DAC/Akt Inhibitor, AR-42

11.14.08

Arno Therapeutics Announces Third Quarter 2008 Financial Results

11.03.08

Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference

10.30.08

Arno Therapeutics Appoints William F. Hamilton to Board of Directors

09.03.08

Arno Therapeutics Announces Appointment of Roger G. Berlin, MD, as Chief Executive Officer and Director

09.03.08

Acquired US patent rights for EDG005

08.18.08

Arno Therapeutics Announces Second Quarter 2008 Financial Results

08.14.08

Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer

08.14.08

Capricor Therapeutics Appoints Thomas Copmann, Ph.D. as Vice President of Regulatory Affairs and Drug Development

07.16.08

Arno Therapeutics Announces New Ticker Symbol

07.15.08

Capricor Therapeutics Announces $7 Million Private Placement of Common Stock

06.05.08

BioWorld Today – Arno Gets $18M Plus Market Access in Reverse Merger

06.05.08

Arno Therapeutics Completes $30.7 Million Financing, Recapitalization and 1-for-8 Reverse Stock Split

06.04.08

Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger

06.04.08

Arno Therapeutics Data Supports Further Evaluation of Onapristone in Prostate Cancer

01.28.08

Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds

01.28.08

Arno Therapeutics Initiates Pharmacokinetic Study for Onapristone Following Regulatory Acceptance – Biotrial to Serve as Contract Research Organization for Paris-Based Trial